Medicine price: quote on request. Every case gets a written custom quote before you commit. Your total cost is quoted per case.
We give you a written timeline estimate for your case before you commit.Get my quote

Kebilidi (eladocagene exuparvovec-tneq): what it is and how families in the Gulf can get it

Creator: Reserve Meds
Published: 2026-10-13

Plain facts from FDA and manufacturer sources, and the legal routes for families in the Gulf.

Reviewed by the Reserve Meds clinical operations team on 13 October 2026.

The short answer

Kebilidi (eladocagene exuparvovec-tneq) is an FDA-approved one-time gene therapy given into the brain made by PTC Therapeutics. The FDA approved it on 13 November 2024 for AADC deficiency. The same therapy was approved earlier in Europe under the name Upstaza, for a narrower group of patients, and in the UK, Israel, Brazil and Taiwan. We found no Gulf registration in public sources as of 13 October 2026. It is given only at specialized treatment centers, so for most Gulf families the realistic route is treatment at a qualified center abroad after a specialist referral. A local hospital can only give it if the manufacturer agrees to supply it and the national regulator approves the import. Plan in months, not weeks (our estimate, not a promise).

About Kebilidi

Generic name: eladocagene exuparvovec-tneq
Made by: PTC Therapeutics
US FDA approval: 13 November 2024
Approved for: adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency
How it is given: a one-time infusion into a part of the brain called the putamen, given during a planned neurosurgical procedure

The FDA decision was based on a trial that measured changes in motor milestones after 48 weeks. Because it is given by neurosurgery, the procedure itself carries surgical risks that the treating team will explain.

Country guides

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate access to FDA-approved medicines only. We help your doctor and hospital prepare the request, arrange US supply and shipping once approval is in place, and keep your family updated. We do not prescribe or give medical advice. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Ask about Kebilidi

Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

What is Kebilidi?

Kebilidi (eladocagene exuparvovec-tneq) is a one-time gene therapy given into the brain made by PTC Therapeutics. The US FDA approved it on 13 November 2024 for adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.

Is Kebilidi approved outside the United States?

The same therapy was approved earlier in Europe under the name Upstaza, for a narrower group of patients, and in the UK, Israel, Brazil and Taiwan. We found no registration in Saudi Arabia, the UAE, Kuwait or Qatar in public sources as of 13 October 2026. A hospital pharmacy should confirm with the national regulator.

Can families in the Gulf get Kebilidi?

Usually by treatment at a qualified center abroad, after a specialist referral. A local hospital can give it only if the manufacturer agrees to supply it and the regulator approves the import.

How much does Kebilidi cost?

Medicine price: quote on request. Your total cost is quoted in writing for your case before you commit. No hidden charges.

What does Reserve Meds do?

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate the paperwork, supply and shipping with your doctor and hospital. We do not prescribe or give medical advice.

Sources

Checked on 13 October 2026. Regulator rules change. Your hospital pharmacy confirms the current procedure before filing.